ClinicalTrials.gg
Active, not recruitingNCT06834347CEREN-1Updated Oct 21, 2026

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

A Phase 3 interventional study of Itepekimab (SAR440340) and Placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Sanofi. Active, not recruiting at 121 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Updated Oct 21, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Nasal Polyps by Sanofi — none open to participants now, 4 under way, 3 of them phase 3. Nasal Polyps · Sanofi.

Enrollment
3rd of 12
231 · median 69
Started
2025
with 2 others
Phase 3
7 of 13
none open now
Registered
9th of 13
by date

Among the 13 studies in Nasal Polyps by Sanofi, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 in phase 3, and was the 9th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

None of the 13 studies in Nasal Polyps by Sanofi is open now. The open studies under Nasal Polyps, anywhere →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Nasal Polyps by Sanofi as a file.
02

Study summary

EFC18418 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups. The purpose of the study is to evaluate the efficacy, safety and tolerability of 2 dosing regimens of itepekimab compared to placebo as add-on therapy to intranasal corticosteroids (INCS) in male and female participants with chronic rhinosinusitis with nasal polyps (CRSwNP) aged 18 years of age and older.

Study details include:

  • The study duration per participant (4-week screening, 52-week treatment, 20-week safety follow-up) will be up to 76 weeks. For participants transitioning to the LTS18420 study, the study duration will be 56 weeks.
  • The treatment duration will be up to 52 weeks.
  • The number of visits will be 9 site visits and 20 phone/home visits.
03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years of age or older.
  • Participants with a history of chronic rhinosinusitis with nasal polyps (CRSwNP) for at least 1 year prior to screening
  • Participants must have at least one of the following features:

    • Prior sinonasal surgery for nasal polyps (NP).
    • Worsening symptoms of chronic rhinosinusitis (CRS) requiring treatment with systemic (s) (SCS) within the prior 1 year before screening (Visit 1).
  • An endoscopic bilateral Nasal Polyp Score (NPS) of at least 5 out of maximum score of 8 (with a minimum score of 2 in each nasal cavity) at screening and randomization.
  • Ongoing symptoms (for at least 12 weeks before Visit 1) of:

    • Nasal congestion/blockade/obstruction with moderate or severe (symptom severity score 2 or 3) at Visit 1 and a weekly average severity of greater than 1 in the week before randomization (Visit 2), AND
    • At least one of the following two symptoms: loss of smell or rhinorrhea (anterior/posterior).
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

    • Is not a women of (WOCBP), OR
    • Is a WOCBP and agrees to use a method that is highly effective, with a failure rate of \<1% during the study (at a minimum until 20 weeks after the last dose of study intervention).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Participants with a history of renal, hepatic, metabolic, neurologic, hematologic, ophthalmologic, respiratory (excluding those with asthma and aspirin-exacerbated respiratory disease (AERD) which may be included in the study), gastrointestinal, cardiovascular, cerebrovascular, or other significant medical illness or disorder, which, in the judgment of the Investigator, could interfere with the study or require treatment that might interfere with the study.
  • Participants who are currently smoking tobacco and/or vaping, or participants in whom smoking/vaping cessation has occurred \<6 months prior to Screening (Visit 1). Nicotine replacement therapy and/or noninhaled tobacco product use are not considered current smoking of tobacco.
  • Participants meet any for mometasone furoate nasal spray (MFNS) such as to MFNS or any of its components; or participants with uncontrolled opportunistic infections.
  • Participants with a history of a severe systemic hypersensitivity reaction to a mAb.
  • Participants with conditions/concomitant diseases making them non-evaluable at Visit 1 or for the primary efficacy endpoint.
  • Participants with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc).
  • Participants with severe uncontrolled asthma with history of 2 and/or more exacerbations, requiring SCS or 1 hospitalization requiring SCS in the past year.
  • History of concomitant lung disease (other than asthma, eg, , interstitial lung disease) which in the opinion of the Investigator could interfere with performance and interpretation of spirometry.
  • Participants treated with intranasal (s) (INCS) (MFNS is permitted), intranasal emitting devices/stents, nasal spray using exhalation delivery system such as XhanceTM during the screening period. In Japan and China INCS other than MFNS are permitted.
  • Participants who have undergone any sinus intranasal surgery (including polypectomy) within 6 months before Visit 1.
  • Participants who received SCS 1 month prior to Screening (Visit 1) or during the screening period (between Visit 1 and Visit 2).
  • Known allergy to itepekimab or its , or any drug or other allergy that, in the opinion of the Investigator, contraindicates participation in this study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
231 participants (actual)

Study arms

  • Experimental
    Itepekimab high dose

    Subcutaneous (SC) administration of Itepekimab high dose for 52 weeks

    Drug: Itepekimab (SAR440340) · Drug: Mometasone furoate nasal spray (MFNS)

  • Experimental
    Itepekimab low dose

    SC administration of Itepekimab low dose for 52 weeks

    Drug: Itepekimab (SAR440340) · Drug: Placebo · Drug: Mometasone furoate nasal spray (MFNS)

  • Placebo comparator
    Placebo

    SC administration of matching placebo for 52 weeks

    Drug: Placebo · Drug: Mometasone furoate nasal spray (MFNS)

Interventions

  • Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

    Also known as: REGN3500

  • DrugPlacebo

    Pharmaceutical form: Solution for injection in prefilled syringe. Route of administration: Subcutaneous

  • Pharmaceutical form: Solution for administration via spray pump. Route of administration: Intranasal spray

06

What researchers measure

Primary outcomes

  1. Change from baseline in the endoscopic NPS

    The Nasal Polyp Score (NPS) is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).

    Time frame: Baseline to Week 24

  2. Change from baseline in the NCS

    The Nasal Congestion Score (NCS) is scored using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Outcome value is defined as the preceding 28-day average of morning scores recorded in eDiary.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Change from baseline in endoscopic NPS

    The NPS is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy. Nasal polyp is graded based on polyp size from 0 to 4 with higher scores indicating larger polyps. The sum of right and left nostril scores ranges from 0 (no polyps) to 8 (large polyps).

    Time frame: Baseline to Week 52

  2. Change from baseline in NCS

    The NCS is scored using a 0-3 categorical scale where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms. Outcome value is defined as the preceding 28-day average of morning scores recorded in eDiary.

    Time frame: Baseline to Week 52

  3. Change from baseline in opacification of sinuses assessed by Computed Tomography (CT) scan using the LMK score

    The Lund-Mackay (LMK) system is based on localization with points given for degree of opacification: 0 = normal, 1 = partial opacification, 2 = total opacification. These points are then applied to the maxillary, anterior ethmoid, posterior ethmoid, sphenoid, frontal sinus on each side. The osteomeatal complex is graded as 0 = not occluded, or 2 = occluded, deriving a maximum score of 12 per side. The total score is the sum of scores from each side and ranges from 0 (normal) to 24 (total opacification).

    Time frame: Baseline to Week 24

  4. Change from baseline in the TSS (nasal congestion/obstruction, anterior/posterior rhinorrhea, and loss of sense of smell)

    The CRSwNP Total Symptom Score (TSS) is a composite score derived from nasal congestion (NC)/obstruction, anterior/posterior rhinorrhea, and loss of smell. The total score ranges from 0 to 9 with higher scores on TSS indicating greater overall symptom severity.

    Time frame: Baseline to Weeks 24 and 52

  5. Change from baseline in loss of smell severity score using the daily CRSwNP sinonasal symptom eDiary, and UPSIT score

    The CRSwNP sinonasal symptom diary is designed to assess the severity of chronic rhinosinusitis (CRS) sinonasal symptoms on daily basis. These symptoms include NC/obstruction, anterior rhinorrhea and posterior rhinorrhea, facial pain/pressure, loss of smell, and headache. Each of the individual items of the diary are scored from 0 ("No symptoms") to 3 ("Severe symptoms - symptoms that are hard to tolerate, cause interference with activities or daily living"). Higher scores on the items of the individual symptoms denote greater symptom severity. The University of Pennsylvania Smell Identification Test (UPSIT) test is a rapid and easy-to-administer method to quantitatively assess human olfactory function. The total score ranges from 0 (anosmia) to 40 (normosmia).

    Time frame: Baseline to Weeks 24 and 52

  6. Change from baseline in SNOT-22 total score

    The Sino-Nasal Outcome Test-22-Items (SNOT-22) is a patient-reported outcome questionnaire designed to assess the impact of CRS on patient's Health-Related Quality of Life (HRQoL). It has 22 items covering five domains: Nasal, Ear/Facial, Sleep, Function, and Emotion. A global score ranging from 0 to 110 with higher score indicating greater rhinosinusitis related health burden.

    Time frame: Baseline to Weeks 24 and 52

  7. Change from baseline in PROMIS SD-SF-8b scores

    The Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form 8b (SD-SF-8b) is a generic 8-item sleep disturbance assessment that evaluates difficulties with falling asleep, staying asleep, and getting enough sleep; and perceptions on the quality and satisfaction of sleep. Scores are calculated with a conversion of the raw score (score range 8 to 40) into a standardized T-score with the mean of the 50 and SD of 10, where higher scores indicate more disturbed sleep.

    Time frame: Baseline to Weeks 24 and 52

  8. Proportion of participants with CRSwNP requiring systemic corticosteroid(s) (SCS) or surgery for CRS

    Time frame: Baseline up to Week 52

  9. Annualized rate of SCS course or surgery for CRS

    Time frame: Baseline up to Week 52

  10. Time to first either SCS or surgery for CRS

    Time frame: Baseline through Week 52

  11. Change from baseline in pre-BD FEV1 (in mL) in participants with co-morbid asthma

    Pre-BD FEV1: pre-bronchodilator forced expiratory volume in 1 second

    Time frame: Baseline to Weeks 24 and 52

  12. Change from baseline in ACQ-5 score in participants with co-morbid asthma

    The Asthma Control Questionnaire (ACQ) is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has 5 questions on the asthma symptoms. The global score is the mean of the item responses and ranges from 0 and 6 with higher score indicating lower asthma control.

    Time frame: Baseline to Weeks 24 and 52

  13. Change from the baseline in NPS and NCS in the subgroup of patients with aspirin-exacerbated respiratory disease (AERD)

    Time frame: Baseline to Weeks 24 and 52

  14. Proportion of participants with AERD requiring SCS or surgery for CRS

    Time frame: Baseline up to Week 52

  15. Annualized rate of SCS course or surgery for CRS in participants with AERD

    Time frame: Baseline up to Week 52

  16. Time to first either SCS or surgery for CRS in participants with AERD

    Time frame: Baseline through Week 52

  17. Change from baseline in pre-BD FEV1 (in ml) in participants with AERD

    Pre-BD FEV1: pre-bronchodilator forced expiratory volume in 1 second

    Time frame: Baseline to Weeks 24 and 52

  18. Proportion of NPS responders (defined as participants with improvement by at least 1 point in NPS)

    Time frame: Weeks 24 and 52

  19. Proportion of NPS responders (defined as participants with improvement by at least 2 points in NPS)

    Time frame: Weeks 24 and 52

  20. Incidence of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), treatment-emergent adverse events of special interest (TEAESIs) and TEAEs leading to treatment discontinuation

    Time frame: Baseline to End of Study (EOS) (Week 72)

  21. Itepekimab concentration in serum

    Time frame: Baseline to EOS (Week 72)

  22. Incidence of treatment-emergent anti-itepekimab antibody (ADA) responses

    Time frame: Baseline to EOS (Week 72)

07

Study locations

121 sites
  • University of Southern California (USC) / Keck Medicine of USC- Site Number : 8400037
    Arcadia, California 91006, United States
  • Sensa Health- Site Number : 8400038
    Los Angeles, California 90006, United States
  • Newport Native MD- Site Number : 8400031
    Newport Beach, California 92663, United States
  • Sacramento Ear Nose & Throat - Roseville- Site Number : 8400064
    Roseville, California 95661, United States
  • Breathe Clear Institute of Sinus and Allergy Relief- Site Number : 8400040
    Torrance, California 90503, United States
  • Orso Health - Torrance - Hawthorne Boulevard- Site Number : 8400035
    Torrance, California 90505, United States
  • Advanced Research Associates (ARA) Professionals- Site Number : 8400011
    Miami, Florida 33176, United States
  • Paradisus Med Research - Miami- Site Number : 8400009
    Miami, Florida 33185, United States
  • Orlando ENT Associates - Orlando- Site Number : 8400008
    Orlando, Florida 32807, United States
  • Emory University School of Medicine- Grady Campus- Site Number : 8400047
    Atlanta, Georgia 30303, United States
  • Treasure Valley Medical Research- Site Number : 8400063
    Boise, Idaho 83706, United States
  • University of Chicago Medical Center- Site Number : 8400018
    Chicago, Illinois 60637, United States
  • Deaconess Clinic Allergy East- Site Number : 8400056
    Evansville, Indiana 47715, United States
  • SSM Health Saint Louis University Hospital- Site Number : 8400005
    St Louis, Missouri 63104, United States
  • Northwell Health Physician Partners Rheumatology at Great Neck- Site Number : 8400028
    Great Neck, New York 11021, United States
  • Essential Medical Research- Site Number : 8400066
    Tulsa, Oklahoma 74137, United States
  • TEN20 Clinical Research - Dallas- Site Number : 8400015
    Dallas, Texas 75244, United States
  • Houston Methodist Hospital- Site Number : 8400054
    Houston, Texas 77030, United States
  • ENT Associates of Texas - McKinne- Site Number : 8400062
    McKinney, Texas 75070, United States
  • Alamo ENT Associates- Site Number : 8400065
    San Antonio, Texas 78258, United States
  • Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400046
    Norfolk, Virginia 23510, United States
  • Investigational Site Number : 0320002
    La Plata, Buenos Aires 1900, Argentina
  • Investigational Site Number : 0320004
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320001
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1638, Argentina
  • Investigational Site Number : 0320003
    Mendoza, 5500, Argentina
  • Investigational Site Number : 0400005
    Graz, 8036, Austria
  • Investigational Site Number : 0400002
    Linz, 4010, Austria
  • Investigational Site Number : 0400001
    Vienna, 1090, Austria
  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760002
    Ribeirão Preto, São Paulo 14049-900, Brazil
  • Centro Internacional de Pesquisa Clínica (CIPES)- Site Number : 0760005
    São José dos Campos, São Paulo 12230-001, Brazil
  • Hospital Israelita Albert Einstein- Site Number : 0760001
    São Paulo, 05651-901, Brazil
  • Investigational Site Number : 1240005
    London, Ontario N6A 4V2, Canada
  • Investigational Site Number : 1240002
    Montreal, Quebec H4a 3j1, Canada
  • Investigational Site Number : 1240001
    Québec, Quebec G1V 4G5, Canada
  • Investigational Site Number : 1520006
    Valdivia, Los Ríos Region 5110683, Chile
  • Investigational Site Number : 1520003
    Talca, Maule Region 3465584, Chile
  • Investigational Site Number : 1520004
    Lo Barnechea, Reg Metropolitana de Santiago 7691236, Chile
  • Investigational Site Number : 1520002
    Santiago, Reg Metropolitana de Santiago 7500692, Chile
  • Investigational Site Number : 1520001
    Santiago, Reg Metropolitana de Santiago 8207257, Chile
  • Investigational Site Number : 1520005
    Viña del Mar, Valparaiso 2540364, Chile
  • Investigational Site Number : 2460004
    Helsinki, 00029, Finland
  • Investigational Site Number : 2460003
    Helsinki, 00130, Finland
  • Investigational Site Number : 2460002
    Kuopio, 70210, Finland
  • Investigational Site Number : 2760004
    Berlin, 10117, Germany
  • Investigational Site Number : 2760007
    Frankfurt, 60318, Germany
  • Investigational Site Number : 2760008
    Hamburg, 22523, Germany
  • Investigational Site Number : 2760009
    Landsberg, 06188, Germany
  • Investigational Site Number : 2760002
    Münster, 48149, Germany
  • Investigational Site Number : 2760001
    Tübingen, 72076, Germany
  • Investigational Site Number : 2760005
    Wiesbaden, 65205, Germany
  • Investigational Site Number : 2760003
    Würzburg, 97080, Germany
  • Investigational Site Number : 3480002
    Budapest, 1046, Hungary
  • Investigational Site Number : 3480004
    Debrecen, 4032, Hungary
  • Investigational Site Number : 3480003
    Nyíregyháza, 4400, Hungary
  • Investigational Site Number : 3480001
    Pécs, 7621, Hungary
  • Investigational Site Number : 3760007
    Haifa, 3436212, Israel
  • Investigational Site Number : 3760004
    Kefar Sava, 4428164, Israel
  • Investigational Site Number : 3760005
    Petah Tikva, 4941492, Israel
  • Investigational Site Number : 3760009
    Tel Aviv, 6423906, Israel
  • Azienda Ospedaliero-Universitaria di Ferrara-Site Number: 3800004
    Cona, Ferrara 44124, Italy
  • Azienda Ospedaliera Universitaria Careggi-Site Number : 3800011
    Florence, Firenze 50134, Italy
  • IRCCS Ospedale Policlinico San Martino-Site Number : 3800013
    Genoa, Genova 16132, Italy
  • ASST Santi Paolo e Carlo-Presidio Ospedale San Paolo-Site Number : 3800006
    Milan, Milano 20142, Italy
  • Azienda Ospedale - Università Padova-Site Number : 3800008
    Padua, Padova 35128, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Site Number: 3800002
    Rome, Roma 00168, Italy
  • Ospedale Bellaria-Site Number: 3800009
    Bologna, 40139, Italy
  • Investigational Site Number : 3920010
    Ichikawa, Chiba 272-0143, Japan
  • Investigational Site Number : 3920004
    Narita, Chiba 286-8520, Japan
  • Investigational Site Number : 3920009
    Isehara, Kanagawa 259-1193, Japan
  • Investigational Site Number : 3920002
    Odawara, Kanagawa 250-8558, Japan
  • Investigational Site Number : 3920014
    Yokohama, Kanagawa 236-0037, Japan
  • Investigational Site Number : 3920005
    Suwa, Nagano 392-0027, Japan
  • Investigational Site Number : 3920012
    Kusatsu, Shiga 525-0066, Japan
  • Investigational Site Number : 3920006
    Fukui, 910-1104, Japan
  • Investigational Site Number : 3920001
    Fukuoka, 812-0053, Japan
  • Investigational Site Number : 3920011
    Hiroshima, 734-0004, Japan
  • Investigational Site Number : 3920003
    Kumamoto, 860-0814, Japan
  • Investigational Site Number : 3920013
    Niigata, 951-8520, Japan
  • Investigational Site Number : 3920008
    Tokyo, 153-8515, Japan
  • Investigational Site Number : 4840004
    Chihuahua City, 31000, Mexico
  • Investigational Site Number : 4840003
    Durango, 34000, Mexico
  • Investigational Site Number : 5280004
    Alkmaar, 1815 JD, Netherlands
  • Investigational Site Number : 5280002
    Leiderdorp, 2353 GA, Netherlands
  • Investigational Site Number : 6160006
    Krakow, Lesser Poland Voivodeship 31-513, Poland
  • Investigational Site Number : 6160001
    Wroclaw, Lower Silesian Voivodeship 53-149, Poland
  • Investigational Site Number : 6160004
    Wroclaw, Lower Silesian Voivodeship 53-301, Poland
  • Investigational Site Number : 6160005
    Lublin, Lublin Voivodeship 20-363, Poland
  • Investigational Site Number : 6160002
    Warsaw, Masovian Voivodeship 00-909, Poland
  • Investigational Site Number : 6160003
    Bialystok, Podlaskie Voivodeship 15-756, Poland
  • Investigational Site Number : 6200003
    Guimarães, 4800-055, Portugal
  • Investigational Site Number : 6200004
    Matosinhos Municipality, 4464-513, Portugal
  • Investigational Site Number : 6200002
    Porto, 3814-501, Portugal
  • Investigational Site Number : 6200001
    Santa Maria da Feira, 4520-211, Portugal
  • Investigational Site Number : 4100005
    Cheonan-Si, Chungcheongnam-do 31116, South Korea
  • Investigational Site Number : 4100009
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Investigational Site Number : 4100008
    Incheon, Incheon-gwangyeoksi 21565, South Korea
  • Investigational Site Number : 4100003
    Seoul, Seoul-teukbyeolsi 03080, South Korea
  • Investigational Site Number : 4100004
    Seoul, Seoul-teukbyeolsi 03722, South Korea
  • Investigational Site Number : 4100002
    Seoul, Seoul-teukbyeolsi 06351, South Korea

Showing the first 100 of 121 sites across 21 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2026, 19 months.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 19 months is below that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Oct 2026 → Sep 2026 and completion Sep 2027 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 19, 2025
StartActual
Feb 12, 2025
Primary completionActual
Sep 23, 2026was Oct 2026
CompletionEst.
Mar 26, 2027was Sep 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 14, 2026→Sep 23, 2026 (actual)
Oct 21, 2026
Study completion
Sep 16, 2027→Mar 26, 2027
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Primary completion Oct 14, 2026→Sep 23, 2026 (now actual)
    Study completion Sep 16, 2027→Mar 26, 2027
    + 3 other changes: verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06834347
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 19, 2025
Start date
Feb 12, 2025
Primary completion
Sep 23, 2026
Completion
Mar 26, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion